| Project/Area Number |
22390118
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Laboratory medicine
|
|---|
| Research Institution | Toyo University (2011-2012)
Juntendo University (2010) |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KATO Kiyoko 九州大学, 医学部, 教授 (10253527)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2012: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2011: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2010: ¥7,410,000 (Direct Cost: ¥5,700,000、Indirect Cost: ¥1,710,000)
|
|---|
| Keywords | 癌 / 腫瘍マーカー / 抗体 / 診断薬 / 婦人科腫瘍 / 卵巣癌 / 子宮体癌 / EpCAM / TROP2 / 癌幹細胞 / エクソソーム / ビーズアレイ |
|---|
| Research Abstract |
We could succeed to generate the target antibody against the gynecologic cancers and to establish a high-sensitive detection system of novel tumor marker. The first, we generated mAb to human NCAM2 expressed on hormone-dependent prostate and breast cancer. In addition, we established seven mAbs against ovarian cancer and one to breast cancer. The second, in attempt to improve diagnosis for gynecologic cancers, we developed new sandwich ELISA and immunochromatography systems detecting human sEpCAM, sCD147, sEphA2 and sTROP2, respectively, with high sensitivity and specificity. The third, we examined the biomarker candidates that were predominantly expressed in cancer stem cells of endometrial cancers. Thus, this approach is feasible for non-invasive and high sensitive diagnosis for gynecologic cancers.
|
